Insights From Technical Analysis
Is Orthocell's (ASX: OCC) Recent Share Price Decline a Warning Sign or a Buying Signal?
Orthocell is a regenerative medicine company expanding Remplir globally, but investors remain cautious because revenue growth is uneven, the business is still loss-making, and U.S. uptake may take time, leaving the stock a higher-risk turnaround opportunity.
SportsHero's (SHO) share price on the move again. How much higher will it go this time?
SportsHero (ASX: SHO) is up over 300%, driven by deals and funding, but is now consolidating after a sharp rally, with further upside dependent on holding support.
PlaySide Studios (ASX: PLY) Strategic Pivot: Where can its share price go after the recent volatility?
PlaySide Studios is shifting from contract development to original IP and publishing to boost margins and growth. Strong partnerships and a solid pipeline support optimism, but revenue volatility and past unprofitability keep investor sentiment cautious.
Massive Volume Surge in Botanix Pharmaceuticals (ASX: BOT): Is it finally finding a bottom?
Botanix Pharmaceuticals has seen a sharp volume spike after a major share price decline, hinting at possible bottoming. While Sofdra sales are growing and funding has improved liquidity, the stock remains in a downtrend, with any recovery dependent on stronger fundamentals and a break above key resistance.
How much higher can the breakout in Liontown's (ASX: LTR) share price take it?
Liontown Resources has rallied on stronger lithium prices, improving production at Kathleen Valley, and a healthier balance sheet after reducing debt. Rising EV and battery demand plus new offtake deals have lifted sentiment. The stock is now approaching key resistance around A$2.20, where the next breakout or pullback will likely be decided.
Invictus Energy (ASX: IVZ): Billion-Barrel Potential or Bust?
Invictus Energy is an early-stage oil and gas explorer in Zimbabwe with large but unproven resource potential. With no revenue and heavy funding needs, the stock offers significant upside if discoveries succeed, but remains a high-risk, news-driven investment.